PRLDNasdaqPharmaceutical PreparationsFiscal year ends December 31

Prelude Therapeutics Inc

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 11, 2026

$3.39+0.13 (+3.99%)

Close on Oct 19, 2026

Market cap: $333.54M
P/E (TTM): –
Dividend yield: –

Prelude Therapeutics Inc income statement

Annual Quarterly TTM

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31	FY 2019 2019-12-31
Revenue	12	7.00	–	–	–	–	–
Research & Development	94	118	103	93	87	48	24
General & Administrative	22	29	29	31	27	11	3.83
Operating Expenses	117	147	132	124	114	59	28
Operating Income	-105	-140	-132	-124	-114	-59	-28
Other Non-Operating Income	5.07	13	10	8.10	2.04	1.83	0.54
Merger & Restructuring Charges	1.32	–	–	–	–	–	–
Gain (Loss) on Sale of Assets	–	–	–	–	–	-0.01	-0.01
Income Tax Expense	0	0	–	–	–	–	–
Net Income incl. Noncontrolling Interests	-99	-127	-122	-115	-112	-57	-28
Net Income	-99	-127	-122	-115	-112	-57	-28
EPS (Basic)(per share)	-1.29	-1.68	-2.02	-2.44	-2.43	-4.56	-16.52
EPS (Diluted)(per share)	-1.29	-1.68	-2.02	-2.44	-2.43	-4.56	-16.52
Shares Outstanding (Basic, Weighted)(shares)	77	76	60	47	46	12	1.67
Shares Outstanding (Diluted, Weighted)(shares)	77	76	60	47	46	12	1.67
EBITDA	-103	-138	-131	-122	-113	-58	-28

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin: –
Operating margin: -300.6%
Net margin: -269.7%
Return on equity, FY2025: -99.5%

Financial strength

Current ratio: 4.07
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 69.2%

Valuation

P/E ratio: –
Price to sales: 14.87
Price to book: 2.49
Dividend yield: –